Approval of Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2026
MANGALAM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mangalam Drugs & Organics reported a massive deterioration in FY26 performance. Revenue from operations declined sharply to Rs 23,213 lakhs from Rs 31,758 lakhs in FY25, a drop of about 27%. The company swung to a net loss of Rs 4,381 lakhs (standalone) and Rs 4,440 lakhs (consolidated) compared to a profit of Rs 692 lakhs in FY25. EPS turned negative at Rs (27.68) per share. The Q4 FY26 standalone loss was Rs 1,306 lakhs. Operating cash flow remained positive at Rs 416 lakhs after working capital adjustments. The auditors issued an unmodified opinion with no qualifications. The company is also pursuing a merger of its subsidiary Mangalam Laboratories and Shri JB Pharma, pending NCLT approval.
The steep revenue decline and significant losses signal serious operational challenges. The stock may face selling pressure as investors digest the losses and declining sales. Low cash reserves of Rs 67 lakhs and increased short-term borrowings to Rs 9,456 lakhs raise liquidity concerns despite positive operating cash flow.